| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFB104A |
| Uniprot No | Q8WTQ1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-72aa |
| 氨基酸序列 | EFELDRICGY GTARCRKKCR SQEYRIGRCP NTYACCLRKW DESLLNRTKP |
| 预测分子量 | 6.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFB104A重组蛋白的模拟参考文献示例(注：以下内容为虚构，仅用于演示格式)：
---
1. **"Recombinant expression and antimicrobial characterization of human β-defensin DEFB104A"**
*Zhang, Y., et al. (2020)*
摘要：本研究在大肠杆菌系统中成功表达并纯化了重组DEFB104A蛋白，证实其对金黄色葡萄球菌和白色念珠菌具有显著抑制作用，提示其在抗感染治疗中的潜在应用。
2. **"DEFB104A modulates TLR4 signaling in macrophages via recombinant protein delivery"**
*Smith, J., & Lee, K. (2018)*
摘要：通过重组DEFB104A蛋白处理巨噬细胞，发现其通过TLR4通路抑制促炎因子IL-6和TNF-α的释放，为炎症性疾病的免疫调节机制提供了新见解。
3. **"Structural insights into DEFB104A by recombinant production and X-ray crystallography"**
*Wang, X., et al. (2021)*
摘要：利用昆虫细胞系统表达DEFB104A重组蛋白，并通过晶体学解析其三维结构，揭示了其独特的电荷分布与抗菌功能的关键结构域。
4. **"Optimization of DEFB104A recombinant production in mammalian expression systems"**
*Chen, L., et al. (2019)*
摘要：对比CHO和HEK293细胞中DEFB104A的表达效率，优化培养条件以提高蛋白产量和稳定性，为大规模生产奠定基础。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“DEFB104A recombinant protein”或“DEFB104A expression”。部分研究可能涉及其同源基因(如DEFB4/DEFB104)的功能探索。
DEFB104A (Defensin Beta 104A), also known as human β-defensin 4 (hBD-4), is a small cationic antimicrobial peptide belonging to the β-defensin family. These evolutionarily conserved proteins play critical roles in innate immunity, acting as host defense peptides against pathogens such as bacteria, fungi, and viruses. DEFB104A is encoded by the DEFB104 gene located on chromosome 8p23.1 and is primarily expressed in epithelial tissues, including the skin, respiratory tract, and urogenital system. Its expression can be upregulated in response to microbial invasion or proinflammatory cytokines, highlighting its role in bridging innate and adaptive immune responses.
Structurally, DEFB104A consists of approximately 50 amino acids, featuring six conserved cysteine residues forming three disulfide bonds that stabilize its β-sheet-rich fold. This compact structure enables interactions with microbial membranes, leading to membrane disruption and pathogen neutralization. Beyond direct antimicrobial activity, DEFB104A exhibits immunomodulatory functions, such as chemoattracting immune cells (e.g., dendritic cells and T lymphocytes) via chemokine receptors like CCR2 and CCR6.
Recombinant DEFB104A protein is produced using expression systems like *E. coli* or mammalian cell lines, often with tags for purification. Its recombinant form allows researchers to study its antimicrobial mechanisms, therapeutic potential, and role in inflammatory diseases. Studies suggest DEFB104A may have broader clinical relevance, including wound healing, combating antibiotic-resistant infections, and modulating mucosal immunity. However, challenges remain in optimizing its stability, minimizing cytotoxicity to host cells, and understanding tissue-specific regulatory pathways. Ongoing research explores its dual role as a microbicidal agent and immune regulator, positioning it as a promising candidate for developing novel antimicrobial or immunotherapeutic strategies.
×
